Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna Report
- Words
- 15
- Chars
- 96
- AI summary
- Yes
Full story
Merck and Moderna have shared detailed results regarding an experimental vaccine. This treatment is designed to address skin cancer. The reports indicate that the vaccine reduces the risk of melanoma recurring.
Merck and Moderna released detailed results on an experimental vaccine to treat the skin cancer.
Open article